

In re Application of:  
Zaghouani  
Application No.: 09/623,728  
Filed: January 22, 2001  
Page 2

PATENT  
Attorney Docket No.: 133-8114005.US04

**Amendments to the Specification:**

Please replace the paragraph beginning at page 28, line 20, with the following paragraph:

All peptides used in the following examples were produced by Research Genetic, Inc. (Huntsville, Alabama) using solid state methodology and purified on HPLC columns to >90% purity using conventional methods. PLP1 peptide (HSLGKWLGH<sup>P</sup>NKF: SEQ ID No:1) encompasses an encephalitogenic sequence corresponding to aa residues 139-151 of naturally occurring proteolipid protein. PLP-LR (HSLGKLLGR<sup>P</sup>NKF:SEQ ID No: 21 is an analog of PLP1 in which Trp144 and His147 were replaced with Leu and Arg (underlined), respectively. PLP1 and PLP-LR bind well to I A<sup>S</sup> class II molecules (i.e. an MHC class II structure produced by a specific strain of mice). PLP2 peptide (NTWTTCQSIAFPSK:SEO ID No: 3) encompasses an encephalitogenic sequence corresponding to aa residues 178-191 of PLP. This peptide also binds to 1-A<sup>S</sup> class II molecules and induces EAE in SJL mice. HA peptide (sequence not shown) corresponds to aa residues 110-120 of the hemagglutinin of the Influenza virus. HA binds to IE" class II molecules and is used here as control peptide.

Please note that the underlining of "L" and "R" in line 23 is intended to be included in the final text and does not indicate an addition of new text. The underlining is identical to that found in the specification as filed. If the form of the amendment is not acceptable, the Examiner is respectfully requested to make the noted change by Examiner's amendment.